Johan Mackenbach Department of Public Health Erasmus MC
|
|
- Calvin Randell McGee
- 7 years ago
- Views:
Transcription
1 Johan Mackenbach Department of Public Health Erasmus MC
2 Improved population health
3 Improved population health Reliable and relevant information
4 Improved population health Reliable and relevant information Proper scientific practices
5 Enormous advances in population health, but: Little progress in some underfunded areas (e.g., neglected tropical diseases ) Modest progress at high costs in some wellfunded areas (e.g., cancer) Progress sometimes comes with large-scale iatrogenic harm (e.g., drug side effects)
6 Enormous increase of available information, but: There is no evidence for most of what we do in medicine Most published research findings are false (Ioannides 2005) Increased skepticism about the claims of evidence-based medicine
7 Enormous increase of quantity and quality of medical and health research, but: Dissatisfaction with emphasis on publication and citation counts Conflicts of interest are omnipresent financial, personal, ideological, Discovery of breaches of scientific integrity suggests dysfunctioning systems
8 Improved population health Reliable and relevant information Proper scientific practices
9 Improved population health Reliable and relevant information Proper scientific practices
10 Improved population health Reliable and relevant information Proper scientific practices
11 Large-scale iatrogenic harm Suppression of research results Financial interests
12 Modest progress at high costs Overemphasis on positive findings Personal interests
13 Because the prior probability of claims being true is usually low Because many studies are biased and underpowered Because there is selective reporting and publishing of positive effects Ioannides 2005
14 Study publication bias arises when studies are published or not depending on their results - Positive results bias : authors are more likely to submit, and editors accept, positive than null results - Filedrawer effect : authors conduct many more studies than they finally report, and do not submit studies with null results Pipeline bias arises when studies without statistically significant results take longer to get published Within-study selective reporting bias arises when only a subset of the original outcome variables are reported Dwan et al. 2008
15 No progress in population health Publication bias Improper scientific practices
16 Artificial discrepancy between supply of study results and volume of high-impact journals ( winner s curse ) Lack of understanding among scientists of links between their practices and research outcomes Dependence of scientists careers, group grant incomes, and institutions reputations on positive results
17 Remove artificial scarcity of publication outlets by creating new, open journals Change editorial policies, e.g., prioritize papers for quality not relevance Obligatory registration of study protocols, and reporting of protocol-based analyses only Awareness raising, research training, codes of conduct, reporting checklists,. Less emphasis on publication and citation counts, wider range of science evaluation criteria Reduce dependence on industry sponsoring, increase public spending on research
18 Remove artificial scarcity of publication outlets by creating new, open journals Change editorial policies, e.g., prioritize papers for quality not relevance Obligatory registration of study protocols, and reporting of protocol-based analyses only Awareness raising, research training, codes of conduct, reporting checklists,. Less emphasis on publication and citation counts, wider range of science evaluation criteria Reduce dependence on industry sponsoring, increase public spending on research
19 Remove artificial scarcity of publication outlets by creating new, open journals Change editorial policies, e.g., prioritize papers for quality not relevance Obligatory registration of study protocols, and reporting of protocol-based analyses only Awareness raising, research training, codes of conduct, reporting checklists,. Less emphasis on publication and citation counts, wider range of science evaluation criteria Reduce dependence on industry sponsoring, increase public spending on research
20 Medical research has contributed and is still contributing to enormous advances in population health We can probably do even better better priorities, better study quality, better reporting, more integrity, Reducing publication bias is important Erasmus MC can contribute by raising research standards and avoiding perverse incentives Academic institutions should join forces to improve publication practices and reduce conflicts of interest
21 Current publication practices have contributed and are still contributing to enormous advances in population health We can probably do even better better priorities, better study quality, better reporting, more integrity, Erasmus MC can contribute to reducing publication bias by raising research standards and avoiding perverse incentives More importantly, academic institutions should join forces to improve publication practices and reduce conflicts of interest
RKI workshop, Evidence based immunisation. Evidence-based methods for public health
RKI workshop, Evidence based immunisation Evidence-based methods for public health ECDC report Evidence-based methods for public health How to assess the best available evidence when time is limited and
More informationNational Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
More informationComment Form: WHO Statement on Public Disclosure of Clinical Trial Results. Suggested Amendment
Form: WHO Statement on Public Disclosure of Clinical Trial Results Page 1 of 6 as individual or on behalf of agency or institution?: Institution er's Name in Full, Title, Institution, City, Country, Tel.,
More informationPROPOSAL by Bangladesh, Barbados, Bolivia and Suriname. Chagas Disease Prize Fund for the Development of New Treatments, Diagnostics and Vaccines
PROPOSAL by Bangladesh, Barbados, Bolivia and Suriname Chagas Disease Prize Fund for the Development of New Treatments, Diagnostics and Vaccines Executive Summary Date: 09.04.15 In resolution WHA 61.21,
More informationSharing public health data: a code of conduct
1 Sharing public health data: a code of conduct In this information age, science is advancing by leaps and bounds. What is driving the exponential growth in knowledge in areas such as genetics, astrophysics,
More informationSharing Data from Large-scale Biological Research Projects: A System of Tripartite Responsibility
Sharing Data from Large-scale Biological Research Projects: A System of Tripartite Responsibility Report of a meeting organized by the Wellcome Trust and held on 14 15 January 2003 at Fort Lauderdale,
More informationTime for Computer Science to Grow Up
Time for Computer Science to Grow Up Lance Fortnow Northwestern University Abstract Unlike every other academic field, Computer Science uses conferences rather than journals as the main publication venue.
More informationTAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
More informationNarrowing the Gap. Clinical Development and Regulatory Pathways for Medical Technologies for Neglected Diseases. Tom Bollyky
Narrowing the Gap Clinical Development and Regulatory Pathways for Medical Technologies for Neglected Diseases Tom Bollyky Stanford Law School Drug Development and International Access Conference April
More informationImproving reporting in randomised trials: CONSORT statement and extensions Doug Altman
Improving reporting in randomised trials: CONSORT statement and extensions Doug Altman Centre for Statistics in Medicine University of Oxford Whatever the outcome of a study, it is really hard for the
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationUniversity of Cincinnati College of Medicine
University of Cincinnati College of Medicine Policy Policy and Guidelines for Industry Relationships Policy and Guidelines for Industry Relationships FAQ Date Updated Page 5/14/2008 2 -- 8 NB: The Institute
More informationThe Coalition s Policy to Protect and Streamline Health and Medical Research Funding
1 Our Plan Real Solutions for all Australians The direction, values and policy priorities of the next Coalition Government. The Coalition s Policy to Protect and Streamline Health and Medical Research
More informationStrong support. Remaining concerns
EORTC opinion on the proposal for an EU Regulation on clinical trials on medicinal products for human use and the 7 th of June ENVI report on this proposal It is clear that the Commission and appointed
More informationAUSTRALIAN INSTITUTE OF HEALTH INNOVATION Faculty of Medicine and Health Sciences. Translating research into medical practice
AUSTRALIAN INSTITUTE OF HEALTH INNOVATION Faculty of Medicine and Health Sciences Translating research into medical practice 2 Translating research into medical practice Techniques and treatments are improving
More informationA Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
More informationWHY THE FDA SHOULD REGULATE TOBACCO PRODUCTS
WHY THE FDA SHOULD REGULATE TOBACCO PRODUCTS WHAT IF a product consumed by nearly 50 million Americans every day killed one-third of those who became regular users and one-half of those who use it for
More informationIssues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?
ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in
More informationManaging Research Compliance Risks
Managing Research Compliance Risks James Moran, J.D., CPA Executive Director of Compliance, University of Pennsylvania School of Medicine Rick Rohrbach, MBA, CPA Senior Manager, Healthcare Consulting Practice
More informationCHALLENGES AND BARRIERS ALONG THE IN-COUNTRY SUPPLY CHAIN
UN Commission on Life-Saving Commodities for Women and Children CHALLENGES AND BARRIERS ALONG THE IN-COUNTRY SUPPLY CHAIN To increase access to life-saving commodities for women and children, barriers
More informationADVANCING POPULATION HEALTH: NEW MODELS AND THE ROLE OF RESEARCH
22 nd Annual Health Care Systems Research Network (HCSRN) Conference (formerly HMO Research Network Conference) ADVANCING POPULATION HEALTH: NEW MODELS AND THE ROLE OF RESEARCH Hosted by: Marshfield Clinic
More informationUniversity of Central Florida College of Medicine Industry Relations Policy and Guidelines. Table of Contents
University of Central Florida College of Medicine Industry Relations Policy and Guidelines 1. Introduction and Scope of Policy 2. Statement of Policy Table of Contents 3. Gifts and Individual Financial
More informationParis, 15 June 2013 Response to a public consultation
Paris, 15 June 2013 Response to a public consultation Revision of the World Medical Association Helsinki Declaration: - transparency of clinical trial results must be enhanced (articles 23, 24 & 26) -
More informationGuidance for Peer Reviewers. The Journal of the American Osteopathic Association (JAOA)
Guidance for Peer Reviewers The Journal of the American Osteopathic Association (JAOA) JAOA Editorial Staff This module is available online at http://jaoa.org/documentlibrary/prmodule.pdf Guidance for
More informationNeal Rouzier responds to the JAMA article on Men and Testosterone
Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationPublication Bias in medical research: issues and communities
Publication Bias in medical research: issues and communities Edgar Schiebel and Maria Elisabeth Züger edgar.schiebel@ait.ac.at, maria-elisabeth.zueger@ait.ac.at AIT Austrian Institute of Technology GmbH,
More informationMarshall University Joan C. Edwards School of Medicine Conflict of Interest Policy. Introduction
Marshall University Joan C. Edwards School of Medicine Conflict of Interest Policy Introduction The faculty 1 and medical students of the Joan C. Edwards School of Medicine (SOM) have responsibilities
More informationCorresponding Author: Daniel Pucheril (email: dpucheril@gmail.com)
PRISMA-P 2015 CHECKLIST ADMINISTRATIVE INFORMATION Title: An updated systematic review of complications following Robotic-Assisted Laparoscopic Radical Prostatectomy: A guide to avoiding and managing complications
More informationFORM ENTRY INSTRUCTIONS FOR THE RESEARCH SEMINARS AND EVENTS WEB PAGE
FORM ENTRY INSTRUCTIONS FOR THE RESEARCH SEMINARS AND EVENTS WEB PAGE ABOUT THE RESEARCH SEMINARS AND EVENTS WEB PAGE The RESEARCH SEMINARS AND EVENTS web page was created to provide a one stop internet
More informationBig Data Analysis & Data Mining
2 nd International Conference on Big Data Analysis & Data Mining San Antonio, USA Nov 30-Dec 02, 2015 Brochure Conference Secretariat 2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA Ph:
More informationPast, present and future issues for the US Preventive Services Task Force. Ned Calonge, M.D., M.P.H. Chair, U.S. Preventive Services Task Force
Past, present and future issues for the US Preventive Services Task Force Ned Calonge, M.D., M.P.H. Chair, U.S. Preventive Services Task Force USPSTF history * USPSTF I: 1984 1989» Followed first report
More information(1) Cancer drug means a prescription drug that is used to treat cancer or the side effects of cancer.
DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT Health Promotion and Disease Prevention Services CANCER DRUG REPOSITORY PROGRAM 6 CCR 1015-10 [Editor s Notes follow the text of the rules at the end of this
More informationRequirements for Drug Information Centres
FIP Pharmacy Information Section Requirements for Drug Information Centres Summary All countries should provide drug information services either independently or as part of a regional network. The service
More informationBig Data Analysis & Data Mining
International Conference on Big Data Analysis & Data Mining Brochure Lexington, USA May 04-06, 2015 Conference Secretariat 5716 Corsa Ave., Suite 110, West Lake, Los Angeles, CA 91362-7354, USA Ph: +1-650-268-9744,
More information16- Master s Degree in Public Health and Public Health Sciences (Majoring Health Management, Planning and Policy)
16- Master s Degree in Public Health and Public Health Sciences (Majoring Health Management, Planning and Policy) Students should fulfill a total of 38 credit hours: 1- Basic requirements: 10 credit hours.
More informationMay 17, 2015. Office of Extramural Research National Institutes of Health 9000 Rockville Pike Bethesda, Maryland 20892
Office of Extramural Research National Institutes of Health 9000 Rockville Pike Bethesda, Maryland 20892 RE: Request for Information (RFI): Optimizing Funding Policies and Other Strategies to Improve the
More informationWorkshop on Establishing a Central Resource of Data from Genome Sequencing Projects
Report on the Workshop on Establishing a Central Resource of Data from Genome Sequencing Projects Background and Goals of the Workshop June 5 6, 2012 The use of genome sequencing in human research is growing
More informationEDITORIAL MINING FOR GOLD : CAPITALISING ON DATA TO TRANSFORM DRUG DEVELOPMENT. A Changing Industry. What Is Big Data?
EDITORIAL : VOL 14 ISSUE 1 BSLR 3 Much has been written about the potential of data mining big data to transform drug development, reduce uncertainty, facilitate more targeted drug discovery and make more
More informationStakeholder Guide 2014 www.effectivehealthcare.ahrq.gov
Stakeholder Guide 2014 www.effectivehealthcare.ahrq.gov AHRQ Publication No. 14-EHC010-EF Replaces Publication No. 11-EHC069-EF February 2014 Effective Health Care Program Stakeholder Guide Contents Introduction...1
More informationEthical Standards for Publication of Aeronautics and Astronautics Research
Ethical Standards for Publication of Aeronautics and Astronautics Research I. Preface/Introduction II. AIAA Ethical Standards A. Ethical Standards for AIAA Journals B. Ethical Standards for AIAA Books
More informationEvaluating New Cancer Treatments
Evaluating New Cancer Treatments You ve just heard about a possible new cancer treatment and you wonder if it might work for you. Your doctor hasn t mentioned it, but you want to find out more about this
More informationWelcome Address by the. State Secretary at the Federal Ministry of Education and Research. Dr Georg Schütte
Welcome Address by the State Secretary at the Federal Ministry of Education and Research Dr Georg Schütte at the "Systems Biology and Systems Medicine" session of the World Health Summit at the Federal
More informationSingapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY
Singapore Clinical Trials Register Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY Clinical Trial Register Global Trend EMA: EU Clinical Trials
More informationElizabeth Wager & Sabine Kleinert. Contact details: liz@sideview.demon.co.uk sabine.kleinert@lancet.com
Responsible research publication: international standards for authors A position statement developed at the 2 nd World Conference on Research Integrity, Singapore, July 22-24, 2010 Elizabeth Wager & Sabine
More informationPost-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
More informationThe Changing Pharmaceutical Sales Landscape: Recommendations for Achieving Compliance and Sales Excellence
The Changing Pharmaceutical Sales Landscape: Recommendations for Achieving Compliance and Sales Excellence By: Wendy Heckelman, Ph.D. Dr. Wendy Heckelman, President and Founder of WLH Consulting, Inc.
More informationEffective Healthcare and The Cochrane Collaboration: Impact
Effective Healthcare and The Cochrane Collaboration: The Vision, The Output, The Impact Dr. Bruce Walker Senior Lecturer in Evidence based practice and Public health School of Chiropractic and Sports Science
More informationCurrent reporting in published research
Current reporting in published research Doug Altman Centre for Statistics in Medicine, Oxford, UK and EQUATOR Network Research article A published research article is a permanent record that will be used
More informationClinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
More informationComponent 2: The Culture of Health Care
Component 2: The Culture of Health Care Unit 9: Sociotechnical Aspects: Clinicians and Technology Lecture 1 This material was developed by Oregon Health & Science University, funded by the Department of
More informationRichard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS
More informationAn Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods
An Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods In considering the safety of chemicals added to foods, or present in foods due to environmental circumstances, we
More informationClinical Trials and Screening: What You Need to Know
Scan for mobile link. Clinical Trials and Screening: What You Need to Know What is a Clinical Trial? At A Glance A clinical trial is a research study that tests how well new medical techniques work in
More informationAntarctic Environmental Portal content development and editorial process
Agenda Item: CEP 3 Presented by: Original: Australia, Belgium, New Zealand, Norway, SCAR English Submitted: 16/04/2015 Antarctic Environmental Portal content development and editorial process 1 Antarctic
More informationApplication of Clinical Trial Certificate of Chinese Medicines in Hong Kong
Application of Clinical Trial Certificate of Chinese Medicines in Hong Kong D R. K F C H U N G D E P A R T M E N T O F P S Y C H I A T R Y U N I V E R S I T Y O F H O N G K O N G ( S E P T 2 0 1 4 ) Evidence-based
More informationGame Changers for Researchers: Altmetrics, Big Data, Open Access What Might They Change? Kiki Forsythe, M.L.S.
Game Changers for Researchers: Altmetrics, Big Data, Open Access What Might They Change? Kiki Forsythe, M.L.S. Definition of Game Changer A newly introduced element or factor that changes an existing situation
More informationANONYMITY AND PSEUDONYMITY IN WHISTLEBLOWING TO THE U.S. OFFICE OF RESEARCH INTEGRITY
ANONYMITY AND PSEUDONYMITY IN WHISTLEBLOWING TO THE U.S. OFFICE OF RESEARCH INTEGRITY ALAN R. PRICE. PHD Reprinted from ACADEMIC MEDICINE, 1998 by H e Association of American Medical Colleges SPECIAL ARTICLE
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationThemes. Why is waste in research an ethical issue? Waste occurs in all stages of research. Research funding is finite
Why is waste in research an ethical issue? Elizabeth Wager PhD Publications Consultant, Sideview, UK Co-Editor-in-Chief : Research Integrity & Peer Review UK EQUATOR Centre Fellow Visiting Professor, University
More informationProfessional Standards and Guidelines
College of Physicians and Surgeons of British Columbia Professional Standards and Guidelines Conflict of Interest Arising from Clinical Research Preamble This document is a guideline of the Board of the
More informationAreas where STATISTICS are used. Government Census, Law, National Defense
What Is Statistics? American Heritage Dictionary: The mathematics of the collection, organization, and interpretation of numerical data, especially the analysis of population characteristics by inference
More informationAdvance Diploma in Pharma Brand Management (ADPBM) TM
Division of Waksman Healthcare & Innoceutical, Mumbai, INDIA PROSPECTUS: 2012-13 Advance Diploma in Pharma Brand Management is an exclusive training program completely on the practical aspects of Pharma
More informationNew Mexico State University
The Office of Research Integrity & Ethics and the Office of Research Compliance Research Integrity and Compliance Human Subjects, Vertebrate Animals, or Biological Agents Luis A. Vazquez, Ph.D. Associate
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationIMPLEMENTING BUSINESS CONTINUITY MANAGEMENT IN A DISTRIBUTED ORGANISATION: A CASE STUDY
IMPLEMENTING BUSINESS CONTINUITY MANAGEMENT IN A DISTRIBUTED ORGANISATION: A CASE STUDY AUTHORS: Patrick Roberts (left) and Mike Stephens (right). Patrick Roberts: Following early experience in the British
More informationPolicy Focus Health Care Regulations Don t Help They Hurt!
Policy Focus Health Care Regulations Don t Help They Hurt! Recipes for Rational Government from the Independent Women s Forum Hadley Heath, Senior Policy Analyst, Independent Women s Forum October 2011
More informationImproving quality, protecting patients
Improving quality, protecting patients Standards of proficiency for Healthcare Science Practitioners 31 July 2014 Version 1.0 Review date: 31 July 2015 Foreword I am pleased to present the Academy for
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationThe Consumer Price Index
The price level is the average level of prices and is measured by using a price index. The consumer price index, or CPI, measures the average level of the prices of goods and services consumed by an urban
More informationRESPONSIBLE CONDUCT OF RESEARCH AND THE GLOBAL CONTEXT
1 RESPONSIBLE CONDUCT OF RESEARCH AND THE GLOBAL CONTEXT An Overview Scientific research is one of the great adventures of our time. Researchers are members of a global community that is producing new
More informationEMORY UNIVERSITY SCHOOL OF MEDICINE POLICY ON INDUSTRY AND OTHER EXTERNAL PROFESSIONAL RELATIONSHIPS. Table of Contents
EMORY UNIVERSITY SCHOOL OF MEDICINE POLICY ON INDUSTRY AND OTHER EXTERNAL PROFESSIONAL RELATIONSHIPS Table of Contents EMORY UNIVERSITY SCHOOL OF MEDICINE POLICY ON INDUSTRY AND OTHER EXTERNAL PROFESSIONAL
More informationThe Board reviews risks to the Company s business plan at its scheduled meetings.
Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board
More informationMedical Liability Task Force
Medical Liability Task Force Report and Recommendations Oregon Health Policy Board November 9, 2010 1 The Board s Charge to the Task Force Investigate the current medical liability system Suggest opportunities
More informationInternational Society of Exposure Science (ISES) Strategic Plan: Creating a Safer and Healthier World by Advancing The Science of Exposure 2008 2011
International Society of Exposure Science (ISES) Strategic Plan: Creating a Safer and Healthier World by Advancing The Science of Exposure 2008 2011 Executive Summary Changes in the field of exposure have
More informationData Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International
Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing,
More informationWhat s Next for Data Sharing: Insight from the NIH Experience
What s Next for Data Sharing: Insight from the NIH Experience Jerry Sheehan Assistant Director for Policy Development National Library of Medicine National Institutes of Health SHARE In-Person Meeting
More informationMaster in Health Services Management
Master in Health Services Management International Centre for Health Management (ICHM) Istituto Superiore di Sanità, Rome In collaboration with Ministry of Foreign Affairs (Italy) Directorate General for
More informationMOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationWhat does the AHSC mean for you?
> > > > > > > > > > > > > > > > > > > > What does the AHSC mean for you? Our vision for the UK s first Academic Health Science Centre a mini-guide for patients Quicker access to new medicines and new treatments
More informationSponsorship Proposal 5K RUN/WALK. to benefit early lung cancer detection research at University of Colorado Cancer Center
Sponsorship Proposal 5K RUN/WALK to benefit early lung cancer detection research at University of Colorado Cancer Center A NATIONAL CANCER INSTITUTE-DESIGNATED Lung cancer is the leading cause of cancer
More informationBACKGROUND TERMS 1. SCOPE OF WORK
PENN STANDARD CLINICAL TRIAL AGREEMENT ORS 05-08 CLINICAL TRIAL RESEARCH AGREEMENT This Agreement is entered into by and between: The Trustees of the University of Pennsylvania with an address at Office
More informationBusiness Continuity for Cyber Threat
Business Continuity for Cyber Threat April 1, 2014 Workshop Session #3 3:00 5:30 PM Susan Rogers, MBCP, MBCI Cyberwise CP S2 What happens when a computer program can activate physical machinery? Between
More informationGenentech Corporate Giving and Grants Tip Sheet Healthcare-Related Charitable Support
Genentech Corporate Giving and Grants Healthcare-Related Charitable Support Table of Contents What is Healthcare-Related Charitable Support... 2 Checklist..... 2 I. Log in... 3 II. Organization Registration
More informationMSc in Toxicology. Master Degree Programme
Master Degree Programme MSc in Toxicology Department of Pharmaceutical Sciences, University of Basel Swiss Centre for Applied Human Toxicology (SCAHT) Master of Science in Toxicology University of Basel
More informationClinician Investigator Program
Clinician Investigator Program Queen s Clinician Investigator Program: Developing the next Overview The Queen s University Clinician Investigator Program (CIP) is an intensive, research-based postgraduate
More informationApplication summary. Lead applicant. Type of Intermediate Fellowship requested. Application title. Proposed duration of funding (months)
Application summary Type of Intermediate Fellowship requested Application title Proposed duration of funding (months) Proposed start date Name of administering organisation Lead applicant's address at
More informationPCORI Methodology Standards: Academic Curriculum. 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved.
PCORI Methodology Standards: Academic Curriculum 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved. Module 5: Step 3 Search the Literature Category 11: Systematic Reviews Prepared
More informationFraud Prevention and Deterrence
Fraud Prevention and Deterrence Fraud Risk Assessment 2016 Association of Certified Fraud Examiners, Inc. What Is Fraud Risk? The vulnerability that an organization faces from individuals capable of combining
More informationEthical Issues in Animal Research
Ethical Issues in Animal Research Overview Perspectives on Animal Research Animal Rights vs. Animal Welfare Benefits of Animal Research Laws and Regulations The IACUC Protocols and the 3 R s AAALAC Accreditation
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationINNOVATING FOR TODAY S HEALTH ECOSYSTEM
THE HONEYBEE CHRONICLES: PART FIVE INNOVATING FOR TODAY S HEALTH ECOSYSTEM An interview with Gregory Downing, Executive Director for Innovation, Immediate Office of the Secretary, United States Department
More informationFifth Scientific Conference for Students of Higher Education in the KSA
Fifth Scientific Conference for Students of Higher Education in the KSA April 28 - May 1, 2014 Riyadh Dr. Khondokar M. Nahiduzzaman Department of City & Regional Planning (CRP), KFUPM October 31, 2013;
More informationCTEP Workshop. An Overview of the NCI s Cancer Therapy and Evaluation Program (CTEP) CTEP s Mission. Workshop Objectives. NCI Organizational Structure
CTEP Workshop Elizabeth Ness, RN, MS Director, Staff Development Center for Cancer Research National Cancer Institute Workshop Objectives At the end of this workshop, participants will be able to: Discuss
More informationWhat is care that works best?
How do we know which types of health care work best? 1 URAC Health Tip Sheets for Consumers This document is part of a series of information resources to help you get good quality health care. For additional
More informationVaccines Research & Development. Exhibitor
International Conference on Vaccines Research & Development Nov 2015 02-04 Baltimore USA Bronze Sponsor Exhibitor Bronze Sponsor : United Scientific Group Welcome Message United Scientific Group takes
More informationData Management Considerations for the Data Life Cycle
Data Management Considerations for the Data Life Cycle NRC STS Panel 2011 November 17, 2011, Washington DC Peter Fox (RPI) foxp@rpi.edu, pfox@cs.rpi.edu Tetherless World Constellation http://tw.rpi.edu
More informationImplementing Evidence-Based Practices in Behavioral Health. Mark P. McGovern, Ph.D. Geisel School of Medicine at Dartmouth
Implementing Evidence-Based Practices in Behavioral Health Mark P. McGovern, Ph.D. Geisel School of Medicine at Dartmouth Implementing Evidence-Based Practices in Behavioral Health Sponsored by the Hazelden
More information